OTC Laxative Recalled Due to Microbial Contamination
At this time, there have been no reports of adverse events related to this recall.
At this time, there have been no reports of adverse events related to this recall.
The approval was based on data from two phase 3 induction studies, and one phase 3 maintenance study.
Vutrisiran is an investigational, subcutaneously-administered RNAi therapeutic designed to block the production of wild-type and mutant transthyretin protein.
Researchers compared low-carbohydrate and low-FODMAP diets to medication in the treatment of IBS
Perrigo received final approval to manufacture Omeprazole Magnesium Delayed-Release Mini Capsules, 20mg.
Ervogastat is a diacylglycerol O-acyltransferase 2 inhibitor and clesacostat is an acetyl-CoA carboxylase inhibitor.
In this meta-analysis, researchers assessed whether an increase in pancreatic enzymes is associated with an increased risk for severe disease and poor outcomes in patients with COVID-19 infection.
Direct inhibition of STAT3 signaling by TTI-101 is expected to lead to reduced tumor growth.
Authors describe efficacy data on the low-FODMAP-diet and CBT for IBS and factors to consider when personalizing treatment.
The NDA submission is supported by data from the phase 2b trial evaluating futibatinib in adults with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR2 gene rearrangements.